NasdaqCM:CELCBiotechs
Celcuity (CELC): Evaluating Valuation After Steepening Quarterly Losses in Latest Financial Results
Celcuity (CELC) just posted its latest quarterly financials, and investors are noticing. The headline here is a much deeper net loss. Celcuity reported a $45 million loss in the second quarter, almost double what it saw a year ago. For the first half of the year, that cumulative net loss grew even higher. While negative earnings are nothing new in early-stage biotech, this marks a clear ramp-up in operating expenses or strategic investment, and it has caught the market’s attention.
This...